Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cardiovascular outcomes of patients treated for non-Hodgkin lymphoma with first-line doxorubicin-based chemotherapy.
Zduniak A, Lévêque E, Perdrix A, Etancelin P, Ménard AL, Lenain P, Contentin N, Pépin LF, Leprêtre S, Lemasle E, Lanic H, Stamatoullas-Bastard A, Kammoun-Quique L, Tilly H, Bauer F, Jardin F, Camus V. Zduniak A, et al. Among authors: stamatoullas bastard a. Leuk Lymphoma. 2022 Dec;63(14):3340-3350. doi: 10.1080/10428194.2022.2123222. Epub 2022 Sep 18. Leuk Lymphoma. 2022. PMID: 36120853
Outcomes after intensive care unit admission in newly diagnosed diffuse large B-cell lymphoma patients: A real-life study.
Zduniak A, Mihailescu SD, Lequesne J, Lenain P, Contentin N, Pepin LF, Ménard AL, Leprêtre S, Lemasle E, Lanic H, Stamatoullas-Bastard A, Tilly H, Tamion F, Jardin F, Camus V. Zduniak A, et al. Among authors: stamatoullas bastard a. Eur J Haematol. 2021 Jun;106(6):788-799. doi: 10.1111/ejh.13606. Epub 2021 Mar 5. Eur J Haematol. 2021. PMID: 33624346 Clinical Trial.
High prevalence of pre-existing sarcopenia in critically ill patients with hematologic malignancies admitted to the intensive care unit for sepsis or septic shock.
Herault A, Lévêque E, Draye-Carbonnier S, Decazes P, Zduniak A, Modzelewski R, Libraire J, Achamrah N, Ménard AL, Lenain P, Contentin N, Grall M, Leprêtre S, Lemasle E, Lanic H, Alani M, Stamatoullas-Bastard A, Tilly H, Jardin F, Tamion F, Camus V. Herault A, et al. Among authors: stamatoullas bastard a. Clin Nutr ESPEN. 2023 Jun;55:373-383. doi: 10.1016/j.clnesp.2023.04.007. Epub 2023 Apr 22. Clin Nutr ESPEN. 2023. PMID: 37202070 Free article.
Survival after Hodgkin lymphoma: causes of death and excess mortality in patients treated in 8 consecutive trials.
Favier O, Heutte N, Stamatoullas-Bastard A, Carde P, Van't Veer MB, Aleman BM, Noordijk EM, Thomas J, Fermé C, Henry-Amar M; European Organization for Research and Treatment of Cancer (EORTC) Lymphoma Group and the Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Favier O, et al. Cancer. 2009 Apr 15;115(8):1680-91. doi: 10.1002/cncr.24178. Cancer. 2009. PMID: 19208428 Free article.
Infradiaphragmatic Hodgkin lymphoma: a large series of patients staged with PET-CT.
Rossi C, Mounier M, Brice P, Safar V, Nicolas-Virelizier E, Rey P, Stamatoullas-Bastard A, Alcantara M, Chauchet A, Reboursière E, Filliatre L, Perrot A, Garciaz S, Salles G, Coiffier B, Ghesquières H, Casasnovas RO. Rossi C, et al. Among authors: stamatoullas bastard a. Oncotarget. 2017 Jul 19;8(49):85110-85119. doi: 10.18632/oncotarget.19389. eCollection 2017 Oct 17. Oncotarget. 2017. PMID: 29156707 Free PMC article.
Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers.
Rossi C, Gilhodes J, Maerevoet M, Herbaux C, Morschhauser F, Brice P, Garciaz S, Borel C, Ysebaert L, Obéric L, Lazarovici J, Deau B, Dupuis J, Chauchet A, Abraham J, Bijou F, Stamatoullas-Bastard A, Malfuson JV, Golfier C, Laurent C, Pericart S, Traverse-Glehen A, Kanoun S, Filleron T, Casasnovas RO, Ghesquières H. Rossi C, et al. Among authors: stamatoullas bastard a. Am J Hematol. 2018 Jun 8. doi: 10.1002/ajh.25154. Online ahead of print. Am J Hematol. 2018. PMID: 29884994 Free article.
First-line escalated BEACOPP does not hinder stem cell collection and transplantation strategy in patients with relapsed/refractory Hodgkin's lymphoma.
Ghez D, Fortpied C, Mounier N, Carde P, Perrot A, Khaled H, Amorim S, Ramadan S, Bras FL, Erlanson M, Herbaux C, Marolleau JP, Nicolas-Virelezier E, Casasnovas O, Stamatoullas-Bastard A, Fermé C. Ghez D, et al. Among authors: stamatoullas bastard a. Bone Marrow Transplant. 2017 Feb;52(2):310-312. doi: 10.1038/bmt.2016.271. Epub 2016 Nov 28. Bone Marrow Transplant. 2017. PMID: 27892946 Clinical Trial. No abstract available.
Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma.
Merryman RW, Kim HT, Zinzani PL, Carlo-Stella C, Ansell SM, Perales MA, Avigdor A, Halwani AS, Houot R, Marchand T, Dhedin N, Lescaut W, Thiebaut-Bertrand A, François S, Stamatoullas-Bastard A, Rohrlich PS, Labussière Wallet H, Castagna L, Santoro A, Bachanova V, Bresler SC, Srivastava A, Kim H, Pesek E, Chammas M, Reynolds C, Ho VT, Antin JH, Ritz J, Soiffer RJ, Armand P. Merryman RW, et al. Among authors: stamatoullas bastard a. Blood. 2017 Mar 9;129(10):1380-1388. doi: 10.1182/blood-2016-09-738385. Epub 2017 Jan 10. Blood. 2017. PMID: 28073785 Free PMC article.
16 results